

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/061256 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:

PCT/US2021/051165

(22) International Filing Date:

21 September 2021 (21.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/081,315 21 September 2020 (21.09.2020) US
63/109,877 05 November 2020 (05.11.2020) US

(71) Applicants: SYSTIMMUNE, INC. [US/US]; 15318 NE 95th St, Redmond, Washington 98052 (US). **BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.** [CN/CN]; Building 1, 161 Baili Road, Wenjiang District, Chengdu, Sichuan 611130 (CN).

(72) Inventors: **GOULET, Dennis R.**; 6788 138th Ave NE #626, Redmond, Washington 98052 (US). **MAK, Nga Sze Amanda**; 9752 Marine View Dr, Mukilteo, Washington

98275 (US). **ZHU, Hai**; 19316 31st DR SE, Bothell, Washington 98012 (US). **ZHU, Yi**; 15318 NE 95th Street, Redmond, Washington 98052 (US).

(74) Agent: **HAN, Zhihua**; EpiMED LLC, 10398 NE 17th St. Unit 306, Bellevue, Washington 98004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: EGFR BINDING COMPLEX AND METHOD OF MAKING AND USING THEREOF

Fig. 1A

```
Consensus QVQLQQSGGPGLVKPSSELSLTCTVSGFSLTNYGVHWVRQAPGKGLWLGVIWSGGNTDYN 60
Cetuximab ...K.....Q...Q...I.....S..... 60
N85E ...K.....Q...Q...I.....S..... 60
H1 E...VE...G...Q...G...R...S.....V..... 60
H2 .....CT...I.....I..... 60
H3 .....V.....CT...I.....I..... 60
H4 .....T...I.....I.....I..... 60
H5 .....L...T...I.....I.....I..... 60
H6 .....L...T...I.....I.....I..... 60
H7 .....T...I.....I.....I..... 60
H8 .....VE...Q...G.....V..... 60
H9 .....VE...Q...G.....V..... 60
H10 .....E.....P.....I..... 60
H11 .....E.....P.....I..... 60

Consensus TFFTSRFTISKDNSKNQVYFKMNSLRAEDTAXYYCARALTYDYEFAYWGQGLTVTVSS 119
Cetuximab .....LS.N.....S..F.....QSN...I.....A 119
N85E .....LS.N.....S..F.....QS...I.....A 119
H1 .....R..T...T...LQ.....V..... 119
H2 .....L...L...V...S...V..... 119
H3 .....T.....L...V...S...V..... 119
H4 .....T.....L...V...S...V..... 119
H5 .....T.....L...V...S...V..... 119
H6 .....T.....L...V...S...V..... 119
H7 .....T.....L...V...S...V..... 119
H8 .....L.....V..... 119
H9 .....L.....V..... 119
H10 .....V.....SL...T.A...V..... 119
H11 .....V.....SL...T.A...V..... 119
```

(57) Abstract: A binding domain having a binding specificity to human EGFR (epithelium growth factor receptor) comprises a VH domain and a VL domain, wherein the VH and VL domain each independently comprises a sequence having at least 90% sequence identity to an amino acid sequence as disclosed thereof. The application further provides antibodies comprising the binding domain.

[Continued on next page]

WO 2022/061256 A2

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*